Latest Conference Articles

September 18th 2020, 9:26pm

ESMO Congress: GU Cancers

The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.

September 18th 2020, 9:23pm

ESMO Congress: Gynecologic Cancers

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

September 18th 2020, 9:20pm

ESMO Congress: Breast Cancer

The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.

September 18th 2020, 9:18pm

ESMO Congress

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

September 14th 2020, 8:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

August 1st 2020, 3:32pm

School of Nursing Oncology

Genetic testing is more important now than ever before, as biomarker-driven cancer treatments continue to receive approval across many tumor types.

August 1st 2020, 12:00am

International Congress on the Future of Breast Cancer West

Although strategies for treating brain metastases in patients with advanced breast cancer are showing signs of efficacy, new approaches are needed to prevent high-risk, HER2-positive early disease from spreading to the central nervous system.

July 31st 2020, 10:14pm

International Congress on the Future of Breast Cancer West

The advent of gene expression assays has provided predictive insight into chemotherapy benefit that can be combined with prognostic information yielded by gene expression profiling to better target patients with breast cancer who are at higher clinical risk for the use of adjuvant chemotherapy.

July 31st 2020, 9:45pm

International Congress on the Future of Breast Cancer West

Joyce A. O'Shaughnessy, MD, discusses the importance of research regarding the application of DNA repair deficiency in breast cancer, even though it's still in early stages.

July 31st 2020, 9:32pm

School of Nursing Oncology

In order to achieve health equity for patients with cancer, physicians must first understand the root cause of heath disparities, many of which may be invisible.

July 31st 2020, 9:30pm

School of Nursing Oncology

Chasity M. Washington, MPH, CHES, discusses ways to mitigate racial disparities in oncology.

July 31st 2020, 9:30pm

School of Nursing Oncology

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

July 31st 2020, 9:10pm

School of Nursing Oncology

One of the most important tasks that oncology nurses face is ensuring that patients are taking their medications consistently and correctly, and that adverse events are properly managed—specifically in those patients with breast cancer.

July 31st 2020, 7:00pm

International Congress on the Future of Breast Cancer West

Debu Tripathy, MD, discusses genomically guided therapy in breast cancer.

July 27th 2020, 10:24pm

International Lung Cancer Congress

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

July 27th 2020, 9:42pm

International Lung Cancer Congress

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

July 27th 2020, 9:41pm

International Lung Cancer Congress

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

July 27th 2020, 9:30pm

International Lung Cancer Congress

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

July 27th 2020, 7:14pm

International Lung Cancer Congress

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

July 24th 2020, 9:40pm

International Lung Cancer Congress

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.